Bosutinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BOSUTINIB |
|---|---|
| Type | Drug |
| Aliases | BosulifБосутиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CML |
| Sources | SRC-ELN-CML-2020 SRC-NCCN-MPN-2025 |
Drug Facts
| Class | BCR-ABL1 / SRC-family TKI (2nd-generation) |
|---|---|
| Mechanism | Dual BCR-ABL1 + SRC inhibitor. Active against most imatinib-resistant mutations except T315I, V299L. Distinct from dasatinib/nilotinib in toxicity profile: GI-dominant (diarrhea), minimal cardiac/pulmonary effects. |
| Typical dosing | CML chronic phase 1L: 400 mg PO once daily with food. 2L+ (post other TKI failure): 500 mg daily. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
2nd-gen TKI option for CML with cardiovascular comorbidity (avoid dasatinib for pulmonary and nilotinib for vascular reasons). AVOID in patients with pre-existing severe GI disease (IBD, baseline diarrhea). NOT registered in Ukraine — significant access barrier.
Used By
Regimens
REG-2GEN-TKI-CML- 2nd-generation TKI (dasatinib OR nilotinib OR bosutinib by comorbidity matrix) — CML chro...